AEMD
Aethlon Medical, Inc.
There isn't enough reported data to score AEMD yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AEMD Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AEMD's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AEMD PE Valuation
AEMD has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AEMD Forward outlook
There aren't enough analyst estimates for AEMD to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AEMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$91.30 | +$337.70 |
| Q4 2025 | -$234.45 | +$381.55 |
| Q3 2025 | -$274.20 | +$837.80 |
| Q2 2025 | -$335.50 | +$1,184.50 |
| Q1 2025 | -$429.00 | +$1,515.00 |
| Q4 2024 | -$616.00 | +$1,380.00 |
| Q3 2024 | -$1,112.00 | +$816.00 |
| Q2 2024 | -$1,520.00 | +$640.00 |
AEMD has the stronger earnings trend. Trailing diluted EPS is down 121% for AEMD versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AEMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2023 | $574.2K | +4278% |
| Q1 2022 | $13.1K | -62% |
| Q4 2021 | $17.1K | -97% |
| Q1 2021 | $34.2K | -83% |
| Q4 2020 | $624.9K | +51% |
AEMD has the stronger quarterly revenue trend. Revenue is up 4,278% for AEMD versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2023 | -432% | +28432 points |
| Q1 2022 | -28863% | -22248 points |
| Q4 2021 | -14769% | -14378 points |
| Q3 2021 | -1522% | N/A |
| Q2 2021 | -1590% | N/A |
| Q1 2021 | -6615% | -5752 points |
| Q4 2020 | -391% | -179 points |
| Q1 2020 | -864% | N/A |
AEMD's operating margin was −432% last quarter, up 1159 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AEMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7M | -$79.9K |
| Q2 2026 | -$1.9M | -$190.8K |
| Q1 2026 | -$1.8M | -$82K |
| Q3 2025 | -$1.7M | +$555.8K |
| Q2 2025 | -$1.7M | +$32.6K |
| Q1 2025 | -$1.7M | +$899.9K |
| Q4 2024 | -$2M | +$373.7K |
| Q3 2024 | -$2.2M | +$496.4K |
AEMD has the stronger cash trend. Its trailing FCF is up 21% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
AEMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +648% | +873K shares |
| 1 year | +2326% | +966K shares |
| 3 years | +19525% | +1M shares |
| 5 years | +33230% | +1M shares |
| Available history | +139451% | +1M shares |
AEMD has 1M diluted shares, up 2326% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AEMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AEMD Net Leverage
AEMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AEMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.9 | Neutral |
| Stochastic | 50.5 | Neutral |
AEMD's weekly RSI is 43 (neutral) and its Stochastic is 51 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AEMD PE vs Healthcare Sector
AEMD has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AEMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.68 | 1.8% below |
| 20 week MA | $4.14 | 35% above |
| 50 week MA | $8.58 | 35% below |
| 100 week MA | $66.1 | 92% below |
| 200 week MA | $452.7 | 99% below |
AEMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AEMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,680.0 | $8,640.0 | +135% |
| 2021 | $8,640.0 | $8,560.0 | -0.9% |
| 2022 | $8,560.0 | $1,004.0 | -88% |
| 2023 | $1,004.0 | $876.0 | -13% |
| 2024 | $876.0 | $242.3 | -72% |
| 2025 | $242.3 | $12.8 | -95% |
| 2026 YTD | $12.8 | $5.58 | -56% |
AEMD has finished five years in a row lower, and it's down 56% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over AEMD on returns for 2026, with the stronger performance.